Horak W, Leithner C, Kemenesi W, Pinggera W
Wien Klin Wochenschr. 1984 Feb 17;96(4):161-5.
The efficacy and safety of a hepatitis B vaccine (Pasteur Institute) has been evaluated in 93 healthy members of the medical staff and in 28 patients undergoing chronic haemodialysis. Following 3 injections of vaccine (each 5 micrograms) at monthly intervals, 94% of the healthy subjects and 61% of the patients were already successfully immunized 4 months after commencement of the vaccination course. Those who did not respond initially received an additional dose at 6 months, which induced seroconversion in several more cases, resulting in the successful immunization of 98% of healthy subjects and 75% of haemodialysis patients. Immune response was sex- and age-dependent. Peak anti-HBs concentrations in responders at 6 months were 643, 325, and 194 mU/ml in healthy women, healthy men, and in patients, respectively. None of the staff members developed clinical or biochemical signs of hepatitis or of any other disease. Markers of hepatitis B virus infection were detected in 3 healthy subjects and in 6 dialysis patients.
一种乙肝疫苗（巴斯德研究所生产）在93名健康医护人员和28名接受慢性血液透析的患者身上进行了疗效和安全性评估。在每月间隔注射3次疫苗（每次5微克）后，94%的健康受试者和61%的患者在疫苗接种疗程开始4个月后已成功免疫。最初无反应者在6个月时额外接种一剂，这又使更多病例发生血清转化，最终98%的健康受试者和75%的血液透析患者成功免疫。免疫反应存在性别和年龄差异。6个月时，健康女性、健康男性和患者中应答者的抗-HBs峰值浓度分别为643、325和194 mU/ml。所有工作人员均未出现肝炎或任何其他疾病的临床或生化体征。在3名健康受试者和6名透析患者中检测到乙肝病毒感染标志物。
